Changeflow GovPing Pharma & Drug Safety IL-8 Signal Inhibitor Composition for Prophylax...
Routine Notice Added Final

IL-8 Signal Inhibitor Composition for Prophylaxis or Treatment of IL-8 Related Diseases

Favicon for changeflow.com USPTO Patent Applications - Peptides (C07K)
Published
Detected
Email

Summary

USPTO published patent application US20260098086A1 on April 9, 2026, covering compositions for prophylaxis or treatment of IL-8 related diseases using IL-8 signal inhibitors and anti-IL-8 antibodies. The application was filed December 5, 2025, by inventors Ayako KAKIUCHI, Atsuhiko Kato, Shuji Hayashi, Izumi Yanagisawa, Ryo Konno, Sachiho Netsu, and Tadashi Sankai. The published application contains CPC classifications related to antibodies and therapeutic compositions.

What changed

USPTO published patent application US20260098086A1 for a composition for prophylaxis or treatment of IL-8 related diseases using IL-8 signal inhibitors and anti-IL-8 antibodies. The application was filed December 5, 2025, and contains CPC classifications covering therapeutic proteins, antibody compositions, and methods of treatment. Patent applicants and pharmaceutical developers should monitor this application's prosecution for potential licensing opportunities or freedom-to-operate considerations.

The publication represents an intellectual property event in the biopharmaceutical space, specifically relating to interleukin-8 (IL-8) targeted therapies. Companies developing anti-inflammatory or immunomodulatory therapeutics should review this publication to assess potential overlaps with their own R&D programs or existing patent portfolios.

What to do next

  1. Monitor for updates on patent prosecution status

Archived snapshot

Apr 12, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES

Application US20260098086A1 Kind: A1 Apr 09, 2026

Inventors

Ayako KAKIUCHI, Atsuhiko Kato, Shuji Hayashi, Izumi Yanagisawa, Ryo Konno, Sachiho Netsu, Tadashi Sankai

Abstract

For example, therapeutic methods and the like for novel IL-8-related diseases using an IL-8 signal inhibitor are provided. Alternatively, for example, therapeutic methods and the like for known or novel IL-8-related diseases using a novel anti-IL-8 antibody are provided.

CPC Classifications

C07K 16/244 A61K 39/395 A61K 45/00 A61P 1/16 A61P 11/00 A61P 13/12 A61P 15/00 A61P 15/08 A61P 17/06 A61P 29/00 A61P 43/00 C07K 16/2866 A61K 2039/505 A61K 2039/507 C07K 16/24 C07K 2317/24 C07K 2317/31 C07K 2317/52 C07K 2317/56 C07K 2317/565 C07K 2317/567 C07K 2317/92 C07K 2317/94

Filing Date

2025-12-05

Application No.

19409997

View original document →

Get daily alerts for USPTO Patent Applications - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260098086A1

Who this affects

Applies to
Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent applications Biopharmaceutical research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!